These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37967875)

  • 1. Adverse Drug Events Associated With Remdesivir in Real-World Hospitalized Patients With COVID-19, Including Vulnerable Populations: A Retrospective Multicenter Study.
    Kang H; Kang CK; Im JH; Cho Y; Kang DY; Lee JY
    J Korean Med Sci; 2023 Nov; 38(44):e346. PubMed ID: 37967875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
    Orogun L; Chyou TY; Nishtala PS
    Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications.
    Charan J; Kaur RJ; Bhardwaj P; Haque M; Sharma P; Misra S; Godman B
    Expert Rev Clin Pharmacol; 2021 Jan; 14(1):95-103. PubMed ID: 33252992
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of baseline renal and hepatic function on the incidence of adverse drug events: the Japan Adverse Drug Events study.
    Takahashi Y; Sakuma M; Murayama H; Morimoto T
    Drug Metab Pers Ther; 2018 Dec; 33(4):165-173. PubMed ID: 30414364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse drug events identified by triggers at a teaching hospital in Brazil.
    Giordani F; Rozenfeld S; Martins M
    BMC Pharmacol Toxicol; 2014 Dec; 15():71. PubMed ID: 25496209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis.
    Santenna C; Vidyasagar K; Amarneni KC; Ghanta SN; Sadasivam B; Pathan S; Padmavathi R
    Ther Adv Drug Saf; 2021; 12():20420986211042517. PubMed ID: 34594487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function.
    Seethapathy R; Wang Q; Zhao S; Strohbehn IA; Long JD; Dinulos JE; Harden D; Kadiyala VB; Moreno D; Sise ME
    PLoS One; 2023; 18(2):e0279765. PubMed ID: 36848366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data.
    Singh A; Kamath A
    Expert Opin Drug Saf; 2021 Dec; 20(12):1559-1564. PubMed ID: 34328807
    [No Abstract]   [Full Text] [Related]  

  • 10. Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019.
    Burwick RM; Yawetz S; Stephenson KE; Collier AY; Sen P; Blackburn BG; Kojic EM; Hirshberg A; Suarez JF; Sobieszczyk ME; Marks KM; Mazur S; Big C; Manuel O; Morlin G; Rose SJ; Naqvi M; Goldfarb IT; DeZure A; Telep L; Tan SK; Zhao Y; Hahambis T; Hindman J; Chokkalingam AP; Carter C; Das M; Osinusi AO; Brainard DM; Varughese TA; Kovalenko O; Sims MD; Desai S; Swamy G; Sheffield JS; Zash R; Short WR
    Clin Infect Dis; 2021 Dec; 73(11):e3996-e4004. PubMed ID: 33031500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Critically Ill Pregnant Patients with COVID-19 Infection in a Rural State.
    Pagan ME; Ramseyer AM; Whitcombe DD; Doiron TE; Magann EF; Sandlin AT; Hughes DS
    Am J Perinatol; 2022 Jan; 39(2):165-171. PubMed ID: 34775583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remdesivir: A Review in COVID-19.
    Blair HA
    Drugs; 2023 Sep; 83(13):1215-1237. PubMed ID: 37589788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
    Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
    J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remdesivir in pregnant women with moderate to severe coronavirus disease 2019 (COVID-19): a retrospective cohort study.
    Arbabzadeh T; Masoumi Shahrbabak M; Pooransari P; Khatuni M; Mirzamoradi M; Saleh Gargari S; Naeiji Z; Rahmati N; Omidi S; Ebrahimi Meimand F
    Clin Exp Med; 2023 Nov; 23(7):3709-3717. PubMed ID: 37277553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Data mining methodology for response to hypertension symptomology-application to COVID-19-related pharmacovigilance.
    Xu X; Kawakami J; Millagaha Gedara NI; Riviere JE; Meyer E; Wyckoff GJ; Jaberi-Douraki M
    Elife; 2021 Nov; 10():. PubMed ID: 34812146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group.
    Bates DW; Spell N; Cullen DJ; Burdick E; Laird N; Petersen LA; Small SD; Sweitzer BJ; Leape LL
    JAMA; 1997 Jan 22-29; 277(4):307-11. PubMed ID: 9002493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hospital admissions caused by adverse drug events: an Australian prospective study.
    Phillips AL; Nigro O; Macolino KA; Scarborough KC; Doecke CJ; Angley MT; Shakib S
    Aust Health Rev; 2014 Feb; 38(1):51-7. PubMed ID: 24351707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of adverse drug events in patients hospitalized in the medical wards of a teaching referral hospital in Ethiopia: a prospective observational study.
    Ersulo TA; Yizengaw MA; Tesfaye BT
    BMC Pharmacol Toxicol; 2022 May; 23(1):30. PubMed ID: 35581618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological treatment in pregnant women with moderate symptoms of coronavirus disease 2019 (COVID-19) pneumonia.
    Nasrallah S; Nguyen AQ; Hitchings L; Wang JQ; Hamade S; Maxwell GL; Khoury A; Gomez LM
    J Matern Fetal Neonatal Med; 2022 Dec; 35(25):5970-5977. PubMed ID: 33771091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019.
    Montastruc F; Thuriot S; Durrieu G
    Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2835-2836. PubMed ID: 32721580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.